• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

26.49 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
News headline image
In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals ↗
May 08, 2024
 
Via Benzinga
News headline image
APLS Stock Earnings: Apellis Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024 ↗
May 07, 2024
APLS stock results show that Apellis Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
May 07, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
May 06, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Expert Ratings For Apellis Pharmaceuticals ↗
April 15, 2024
 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,000 Today ↗
April 10, 2024
 
Via Benzinga
News headline image
$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,000 Today ↗
March 29, 2024
 
Via Benzinga
News headline image
Decoding 15 Analyst Evaluations For Apellis Pharmaceuticals ↗
March 27, 2024
 
Via Benzinga
News headline image
Apellis Announces 11 Oral Presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 01, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
April 26, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Host Conference Call on May 7, 2024, to Discuss First Quarter 2024 Financial Results
April 23, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Peering Into Apellis Pharmaceuticals's Recent Short Interest ↗
March 15, 2024
 
Via Benzinga
News headline image
Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (18 Ratings) ↗
February 28, 2024
 
Via Benzinga
News headline image
The 5 Stocks Most Sold By Insiders This Year
April 16, 2024
Insiders are selling these 5 stocks increased as their markets advanced, and gains may be capped. Long-term outlooks are positive for growth and share prices. 
Via MarketBeat
News headline image
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Host a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
April 01, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For February 27, 2024 ↗
February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
News headline image
Here's How Much You Would Have Made Owning Apellis Pharmaceuticals Stock In The Last 5 Years ↗
February 22, 2024
 
Via Benzinga
News headline image
$1000 Invested In Apellis Pharmaceuticals 5 Years Ago Would Be Worth This Much Today ↗
February 05, 2024
 
Via Benzinga
News headline image
Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know ↗
January 30, 2024
 
Via Benzinga
News headline image
Apellis Appoints Leading Expert Dr. Philip Ferrone as Chief Medical Retina Advisor
March 11, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
March 06, 2024
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place 
Via MarketBeat
News headline image
ICU Medical To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
February 28, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
February 26, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals to Host Conference Call on February 27, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results
February 20, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Pinterest To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Monday ↗
February 05, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
January 26, 2024
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap